Thymosin Beta 4 Designated Orphan Drug for Eye Disorder
RegeneRx Biopharmaceuticals announced that the FDA has granted its drug candidate, Thymosin beta 4 (Tβ4) Orphan Drug designation for the treatment of neurotrophic keratopathy (NK). Tβ4 is a novel therapeutic peptide being developed for tissue and organ protection, repair, and regeneration.
Neurotrophic keratopathy is a serious degenerative disease of the corneal epithelium. A reduction in corneal sensitivity or complete corneal anesthesia is the hallmark of this disease and is responsible for producing corneal ulceration, perforation, pain and impaired vision.RegeneRx.com.